NIH to Review Intramural Program
NCI’s Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level
NIH has launched a systematic examination of its intramural program, which accounts for 11.1 percent of its $30 billion budget.
The program was last examined in 1993, pursuant to a mandate from the House Appropriations Committee.
That examination was written by a panel co-chaired by Paul Marks, then president of Memorial Sloan-Kettering Cancer Center and Gail Cassell, then chair of the University of Alabama Department Microbiology.
|President Requests Extra $200 Mil for NIH|
President Barack Obama’s $3.9-trillion budget proposal for the 2015 fiscal year would bump NIH funding up to $30.2 billion—a $200 million increase over fiscal 2014—and would include an additional $8 million for NCI, totaling $4.931 billion for the institute.
|HPV Vaccines Should be Priority, says President’s Cancer Panel|
Human papillomavirus vaccines are underused in the U.S. and need to be made a national public health priority, according to a report from the President’s Cancer Panel.
In a presentation to the National Cancer Advisory Board Feb. 27, panel chair Barbara Rimer outlined three goals to accelerate uptake of HPV vaccines, including having providers strongly encourage HPV vaccination to adolescents when other vaccines are being administered.
|NCI Publishes Report on Pancreatic Cancer|
NCI has issued a report detailing a “scientific framework” for advancing research on pancreatic ductal adenocarcinoma, indicating potential new funding opportunities for genomic studies for early detection of pancreatic cancer.
The institute’s report is the result of the Recalcitrant Cancer Research Act, a bill proposed by the Pancreatic Cancer Action Network, and passed Jan. 2, 2013.
- Pasche named center director at Wake Forest Baptist Medical Center
- Jiali Han named Rachel Cecile Efroymson Professor in Cancer Research at the Indiana University Simon Cancer Center
- Carol Bier-Laning will lead CTCA Head and Neck Cancer Program
- Curie-Cancer renews partnership with DNA Therapeutics
- A correction